Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $100.00 price objective on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on the company. Chardan Capital lifted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada boosted their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. B. Riley Financial lifted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Morgan Stanley increased their price objective on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Finally, Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Stock Up 0.4%

Arrowhead Pharmaceuticals stock opened at $62.92 on Tuesday. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $76.76. The stock has a fifty day simple moving average of $67.09 and a two-hundred day simple moving average of $44.49. The firm has a market cap of $8.81 billion, a price-to-earnings ratio of 41.12 and a beta of 1.21. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million for the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. Arrowhead Pharmaceuticals’s quarterly revenue was up 10461.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.39) earnings per share. Equities analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 40,164 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the sale, the insider owned 171,958 shares of the company’s stock, valued at $10,852,269.38. This trade represents a 18.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Patrick O’brien sold 49,493 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the sale, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at $29,971,443.88. This represents a 9.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 510,836 shares of company stock worth $33,603,060. 3.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after purchasing an additional 300,000 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company’s stock valued at $216,799,000 after buying an additional 133,921 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after buying an additional 2,017,489 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.